80 related articles for article (PubMed ID: 21095545)
1. Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review.
Christ E; Wild D; Reubi JC
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):791-800. PubMed ID: 21095545
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.
Wild D; Christ E; Caplin ME; Kurzawinski TR; Forrer F; Brändle M; Seufert J; Weber WA; Bomanji J; Perren A; Ell PJ; Reubi JC
J Nucl Med; 2011 Jul; 52(7):1073-8. PubMed ID: 21680696
[TBL] [Abstract][Full Text] [Related]
3. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
4. Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.
Waser B; Reubi JC
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1054-8. PubMed ID: 21210113
[TBL] [Abstract][Full Text] [Related]
5. Innovative imaging of insulinoma: the end of sampling? A review.
Christ E; Antwi K; Fani M; Wild D
Endocr Relat Cancer; 2020 Apr; 27(4):R79-R92. PubMed ID: 31951592
[TBL] [Abstract][Full Text] [Related]
6. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications.
Körner M; Christ E; Wild D; Reubi JC
Front Endocrinol (Lausanne); 2012; 3():158. PubMed ID: 23230431
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
Christ E; Wild D; Forrer F; Brändle M; Sahli R; Clerici T; Gloor B; Martius F; Maecke H; Reubi JC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4398-405. PubMed ID: 19820010
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
10. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208
[TBL] [Abstract][Full Text] [Related]
11. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
Wicki A; Wild D; Storch D; Seemayer C; Gotthardt M; Behe M; Kneifel S; Mihatsch MJ; Reubi JC; Mäcke HR; Christofori G
Clin Cancer Res; 2007 Jun; 13(12):3696-705. PubMed ID: 17575235
[TBL] [Abstract][Full Text] [Related]
12. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
13. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
14. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2318-2327. PubMed ID: 30054698
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
During MJ; Cao L; Zuzga DS; Francis JS; Fitzsimons HL; Jiao X; Bland RJ; Klugmann M; Banks WA; Drucker DJ; Haile CN
Nat Med; 2003 Sep; 9(9):1173-9. PubMed ID: 12925848
[TBL] [Abstract][Full Text] [Related]
16. CXCL12/SDF-1 over-expression in human insulinomas and its biological relevance.
Ilhan A; Nabokikh A; Maj M; Vidakovic M; Nielsen JH; Prikoszovich T; Niederle B; Base W; Luger A; Wagner L
Mol Cell Endocrinol; 2009 Jan; 298(1-2):1-10. PubMed ID: 19013212
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass.
Reubi JC; Perren A; Rehmann R; Waser B; Christ E; Callery M; Goldfine AB; Patti ME
Diabetologia; 2010 Dec; 53(12):2641-5. PubMed ID: 20835917
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis.
Marzioni M; Alpini G; Saccomanno S; Candelaresi C; Venter J; Rychlicki C; Fava G; Francis H; Trozzi L; Glaser S; Benedetti A
Gastroenterology; 2007 Jul; 133(1):244-55. PubMed ID: 17631146
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor.
Wu Z; Todorov I; Li L; Bading JR; Li Z; Nair I; Ishiyama K; Colcher D; Conti PE; Fraser SE; Shively JE; Kandeel F
Bioconjug Chem; 2011 Aug; 22(8):1587-94. PubMed ID: 21692471
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
